Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Thoracic 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Leukemia 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 13fludarabine phosphate 10Etoposide 8Methotrexate 7Cyclophosphamide 7Busulfan 7Idarubicin 6Daunorubicin 6tipifarnib 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5Cyclosporine 5Antilymphocyte Serum 5Vorinostat 4Tacrolimus 4Radiotherapy 4Mitoxantrone 4Lenalidomide 4Epoetin Alfa 4Azacitidine 4sargramostim 3merphos 3epoetin beta 3Topotecan 3Thioguanine 3Methylprednisolone 3Granulocyte-Macrophage Colony-Stimulating Factor 3Dexamethasone 3Decitabine 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × DNA Methylation × Classical hematology × Clear all
NCT00454480 2013-08-26

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 2/3 Completed
2,000 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡